GRNA Market Overview:
As per MRFR analysis, the GRNA Market Size was estimated at 2.47 (USD Billion) in 2022. The GRNA Market is expected to grow from 2.65 (USD Billion) in 2023 to 5.0 (USD Billion) by 2032. The GRNA Market CAGR (growth rate) is expected to be around 7.3% during the forecast period (2024 - 2032).
Key GRNA Market Trends Highlighted
Genome Editing Technologies (GETs) are rapidly advancing, and among them, guide RNA (GRNA) has emerged as a crucial component, enabling precise targeting and editing of genetic material.
The GRNA Market is set to flourish in the coming years, influenced by key factors such as growing investments in gene therapy research, regulatory approvals, and increasing disease prevalence. The integration of GRNA with advanced technologies like CRISPR-Cas9 and piggyBac has further fuelled its potential in targeted genomic modifications.
Opportunities abound in the GRNA market, with novel applications in diagnostics, synthetic biology, and agricultural biotechnology. Startups and established players are actively exploring new avenues, such as the development of multiplexed GRNAs for complex genetic circuits and the integration of GRNA into RNA-based therapeutics.
Recent trends include the emergence of synthetic GRNAs with enhanced specificity and efficiency, as well as the development of GRNA libraries for high-throughput screening.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
GRNA Market Drivers
Increasing Prevalence of Genetic Diseases
The rising incidence of genetic disorders worldwide is a major factor driving the growth of the GRNA Market. Genetic diseases are caused by mutations in genes, which can lead to a wide range of health problems, including cancer, heart disease, and neurological disorders.
As the population ages and medical technology advances, more and more genetic diseases are being diagnosed. This is creating a growing demand for genetic testing and counseling, which in turn is driving the growth of the GRNA Market. According to the World Health Organization (WHO), genetic diseases affect approximately 300 million people worldwide.
In the United States, it is estimated that 1 in 10 people has a genetic disorder. The most common genetic diseases include sickle cell anemia, cystic fibrosis, and Down syndrome. The increasing prevalence of genetic diseases is a major concern for healthcare systems around the world.
As the population ages and more people are diagnosed with genetic disorders, the demand for genetic testing and counseling will continue to grow. This will create significant opportunities for growth in the GRNA Market.
Technological Advancements in Genetic Testing
The development of new and innovative genetic testing technologies is another major factor driving the growth of the GRNA Market. These technologies are making it faster, cheaper, and easier to diagnose genetic diseases.
This is leading to a wider range of genetic testing options for patients, which is, in turn, driving the demand for GRNA testing. One of the most significant technological advancements in genetic testing is the development of next-generation sequencing (NGS).
NGS is a high-throughput sequencing technology that can sequence millions of DNA fragments in a single experiment. This has made it possible to sequence the entire human genome for a fraction of the cost of traditional Sanger sequencing.
NGS is being used to identify genetic mutations that are associated with a wide range of diseases, including cancer, heart disease, and neurological disorders. This information is being used to develop new diagnostic tests, treatments, and preventive measures for genetic diseases.
Rising Demand for Personalized Medicine
The growing demand for personalized medicine is also driving the growth of the GRNA Market. Personalized medicine is an approach to healthcare that uses genetic information to tailor medical treatment to the individual patient.
This approach has the potential to improve the effectiveness and safety of medical treatments, and it is also leading to the development of new drugs and therapies. GRNA testing is a key component of personalized medicine.
GRNA testing can be used to identify genetic mutations that are associated with a particular disease. This information can then be used to develop personalized treatment plans for patients. For example, GRNA testing can be used to identify patients who are at risk of developing breast cancer. This information can then be used to develop preventive measures, such as increased screening and prophylactic surgery.
GRNA Market Segment Insights:
GRNA Market Region Insights
The GRNA Market segmentation provides valuable insights into the regional distribution of market growth. Asia Pacific is projected to dominate the GRNA Market, with a market size of USD 1.25 Billion in 2023 and an estimated CAGR of 8.5% from 2024 to 2032.
Factors such as rising disposable income, increasing healthcare expenditure, and growing awareness of genetic testing are driving the market expansion in this region. North America is another major market, with a market size of USD 0.75 Billion in 2023 and an estimated CAGR of 7.0% from 2024 to 2032.
The presence of key players and advanced healthcare infrastructure contribute to the region's significant share in the GRNA Market. Europe is a mature market for GRNA, with a market size of USD 0.40 Billion in 2023 and an estimated CAGR of 6.5% from 2024 to 2032.
The region's well-established healthcare systems and high adoption of genetic testing services are driving market growth. South America and the Middle East and Africa are emerging markets with a growing demand for GRNA. The market size in South America is expected to reach USD 0.20 Billion by 2032, with a CAGR of 9.0% from 2024 to 2032.
In the Middle East and Africa, the market is expected to reach USD 0.15 Billion by 2032, with a CAGR of 10.0% from 2024 to 2032. Increasing healthcare investments and government initiatives are expected to fuel market growth in these regions.
Overall, the GRNA Market is poised for significant growth in the coming years, driven by factors such as rising healthcare expenditure, technological advancements, and increasing healthcare awareness.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
GRNA Market Type Insights
The GRNA Market revenue is expected to have remarkable growth in the coming years. The market is segmented into various types, with Crude Glycerol and Distillate Glycerol being the two major types. Crude Glycerol is expected to dominate the market in the coming years due to its versatility and cost-effective nature.
The GRNA Market segmentation provides insights into the market dynamics, helping businesses make informed decisions. According to GRNA Market data, the market for Crude Glycerol is expected to grow at a CAGR of 6.5% from 2024 to 2032, reaching a market size of USD 2.5 billion by 2032.
On the other hand, Distillate Glycerol is expected to grow at a CAGR of 7.2% during the same period, reaching a market size of USD 1.8 billion by 2032. This growth is primarily attributed to the increasing demand for bio-based products and the growing adoption of glycerol in various industries such as food and beverages, pharmaceuticals, and personal care.
GRNA Market Application Insights
The GRNA Market segmentation by Application includes Food and Beverage, Personal Care, Pharmaceuticals, and Industrial. The Food and Beverage segment is expected to dominate the market with a revenue of USD 1.2 billion in 2024, growing at a CAGR of 7.5%.
The Personal Care segment is projected to witness the highest growth rate of 8.2% over the forecast period, owing to the rising demand for natural and organic personal care products. The Pharmaceuticals segment held a significant share in 2023 and is estimated to maintain its position throughout the forecast period due to the increasing use of GRNA in drug discovery and development.
The Industrial segment is anticipated to contribute substantially to the overall market growth, driven by its applications in packaging, coatings, and adhesives.
GRNA Market Distribution Channel Insights
The GRNA Market is segmented based on distribution channels into B2B and B2C. B2B segment accounted for a larger share of the GRNA Market in 2023, owing to the increasing demand from industries such as pharmaceuticals, cosmetics, and food beverages.
The B2B segment is expected to continue to dominate the market over the forecast period, with a CAGR of 7.5%. The growth of the B2B segment can be attributed to the increasing adoption of GRNA by businesses to improve their operational efficiency and reduce costs. The B2C segment is also expected to witness significant growth over the forecast period, owing to the rising awareness about the benefits of GRNA among consumers.
The growth of the B2C segment can be attributed to the increasing disposable income of consumers and the growing trend of online shopping.
GRNA Market End Use Insights
The GRNA Market segmentation by End Use is broadly classified into commercial, industrial, and residential sectors. Among these, the industrial sector is anticipated to account for the largest revenue share by 2026, owing to the growing demand for GRNA in various industrial applications such as construction, automotive, and manufacturing. The increasing adoption of GRNA in commercial buildings and residential complexes is also expected to drive the growth of the market.
GRNA Market Regional Insights
The GRNA Market is segmented into North America, Europe, APAC, South America, and MEA. Among these regions, North America is expected to hold the largest market share in 2023, owing to the presence of major pharmaceutical and biotechnology companies and a high prevalence of chronic diseases. Europe is expected to be the second-largest market, followed by APAC.
The APAC region is expected to witness the highest growth rate during the forecast period due to the increasing prevalence of chronic diseases and rising healthcare expenditure. South America and MEA are expected to account for a smaller share of the global market but are expected to grow at a steady pace.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
GRNA Market Key Players and Competitive Insights:
Major players in the GRNA Market are constantly looking for innovative ways to improve their competitive edge. Some of the key strategies adopted by leading GRNA Market players include expanding their product portfolio, entering into strategic partnerships, investing in research and development, and leveraging technology to enhance their operations.
The competitive landscape of the GRNA Market development is expected to remain dynamic in the coming years, with key players vying for market share and innovation.
Vertex Pharmaceuticals is a leading player in the GRNA Market Competitive Landscape, with a strong focus on the development and commercialization of treatments for serious diseases. The company's lead product, Orkambi, is a combination therapy approved for the treatment of cystic fibrosis in patients who have two copies of the F508del mutation in the CFTR gene.
Orkambi has been commercially successful, generating significant revenue for Vertex. The company has also expanded its product pipeline through strategic acquisitions and partnerships, including the acquisition of Semma Therapeutics and the collaboration with CRISPR Therapeutics.
Editas Medicine is a competitor in the GRNA Market Competitive Landscape that is focused on the development of gene editing therapies for a variety of genetic diseases. The company's lead product, EDIT-101, is a CRISPR-based gene editing therapy for the treatment of sickle cell disease.
EDIT-101 has shown promising results in clinical trials, and Editas Medicine is currently seeking regulatory approval for the therapy. The company has also expanded its pipeline through strategic partnerships, including a collaboration with Allergan to develop gene-editing therapies for ophthalmic diseases.
Key Companies in the GRNA Market Include:
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- QIAGEN
- Synthego Corporation
- GenScript Biotech Corporation
- PacBio
- Integrated DNA Technologies
- Roche Holding
- Twist Bioscience Corporation
- Eurofins Scientific SE
- Bionano Genomics, Inc.
- IDT
- Ginkgo Bioworks
- Merck KGaA
GRNA Market Developments
Recent developments in the market include the growing adoption of gene editing technologies, increasing investment in research and development, and the emergence of new players. Key market trends include the rising prevalence of genetic diseases, the development of personalized medicine, and the increasing use of gene editing in agriculture. Major players in the market include Thermo Fisher Scientific, Merck KGaA, Cellecta, and Horizon Discovery Group.
GRNA Market Segmentation Insights
- GRNA Market Region Outlook
- Asia Pacific
- North America
- Europe
- South America
- Middle East and Africa
- GRNA Market Type Outlook
- Crude Glycerol
- Distillate Glycerol
- GRNA Market Application Outlook
- Food and Beverage
- Personal Care
- Pharmaceuticals
- Industrial
- GRNA Market Distribution Channel Outlook
- B2B
- B2C
- GRNA Market End Use Outlook
- Commercial
- Industrial
- Residential
- GRNA Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
2.47(USD Billion) |
| Market Size 2023 |
2.65(USD Billion) |
| Market Size 2032 |
5.0(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
7.3% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., QIAGEN, Synthego Corporation, GenScript Biotech Corporation, PacBio, Integrated DNA Technologies, Roche Holding, Twist Bioscience Corporation, Eurofins Scientific SE, Bionano Genomics, Inc., IDT, Ginkgo Bioworks, Merck KGaA |
| Segments Covered |
Region, Type, Application, Distribution Channel, End Use, Regional |
| Key Market Opportunities |
CRISPR-Cas gene editing, RNAi therapeutics, personalized medicine, and agricultural biotechnology diagnostics |
| Key Market Dynamics |
Rising demand for CRISPR-based therapies Technological advancements in genome editing Growing prevalence of genetic disorders Increasing government funding for gene therapy research Strategic collaborations and acquisitions by market players |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The GRNA Market reached a valuation of 2.65 billion USD in 2023.
The GRNA Market is projected to grow at a CAGR of 7.3% from 2024 to 2032.
The GRNA Market is expected to reach a valuation of 5.0 billion USD by 2032.
North America is expected to hold the largest market share in the GRNA Market throughout the forecast period.
The GRNA Market is primarily driven by the increasing demand for GRNA in the medical field.
Key competitors in the GRNA Market include Merck, Pfizer, and Novartis.
